{"transactions":[{"id":3434004,"issuer":{"id":90033,"kind":"organization","name":"Deciphera Pharmaceuticals, Inc.","symbol":"NA"},"owners":[{"id":93222,"kind":"person","name":"New Leaf Venture Management III, L.L.C.","position":1,"cik":"0001625657","reported_name":"New Leaf Venture Management III, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93220,"kind":"person","name":"New Leaf Ventures III, L.P.","position":2,"cik":"0001625653","reported_name":"New Leaf Ventures III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":155397,"kind":"organization","name":"New Leaf Biopharma Opportunities I, L.P.","position":3,"cik":"0001625696","reported_name":"New Leaf Biopharma Opportunities I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93221,"kind":"person","name":"New Leaf Venture Associates III, L.P.","position":4,"cik":"0001625656","reported_name":"New Leaf Venture Associates III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":155398,"kind":"organization","name":"New Leaf BPO Associates I, L.P.","position":5,"cik":"0001625693","reported_name":"New Leaf BPO Associates I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-08-19T16:35:47.000Z","date":"2019-08-16","kind":"sale","acquired":false,"shares":28626,"price":37.0148,"value":1059585.6648,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.00 to $37.32, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (5) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"The reportable securities are owned directly by New Leaf Biopharma Opportunities I, L.P. (\"Biopharma I\"). New Leaf BPO Associates I, L.P. (\"NLBA I\") is the sole general partner of Biopharma I. NLV Management III is the sole general partner of NLBA I. NLVP is the investment adviser of Biopharma I. Each of NLBA I and NLV Management III disclaim beneficial ownership of these securities and this report shall not be deemed an admission that NLBA I or NLV Management III are beneficial owners of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"(Continuation from footnote 6) Each of the Members may be deemed to have shared voting and dispositive power of these securities. Each of the Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":1963258,"source":{"system":"sec-edgar","filing":"0000899243-19-022047","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1625657/000089924319022047/doc4.xml","form_type":"4"}},{"id":3434003,"issuer":{"id":90033,"kind":"organization","name":"Deciphera Pharmaceuticals, Inc.","symbol":"NA"},"owners":[{"id":93222,"kind":"person","name":"New Leaf Venture Management III, L.L.C.","position":1,"cik":"0001625657","reported_name":"New Leaf Venture Management III, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93220,"kind":"person","name":"New Leaf Ventures III, L.P.","position":2,"cik":"0001625653","reported_name":"New Leaf Ventures III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":155397,"kind":"organization","name":"New Leaf Biopharma Opportunities I, L.P.","position":3,"cik":"0001625696","reported_name":"New Leaf Biopharma Opportunities I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93221,"kind":"person","name":"New Leaf Venture Associates III, L.P.","position":4,"cik":"0001625656","reported_name":"New Leaf Venture Associates III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":155398,"kind":"organization","name":"New Leaf BPO Associates I, L.P.","position":5,"cik":"0001625693","reported_name":"New Leaf BPO Associates I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-08-19T16:35:47.000Z","date":"2019-08-16","kind":"sale","acquired":false,"shares":75974,"price":36.5433,"value":2776340.6742,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.00 to $36.995, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"The reportable securities are owned directly by New Leaf Biopharma Opportunities I, L.P. (\"Biopharma I\"). New Leaf BPO Associates I, L.P. (\"NLBA I\") is the sole general partner of Biopharma I. NLV Management III is the sole general partner of NLBA I. NLVP is the investment adviser of Biopharma I. Each of NLBA I and NLV Management III disclaim beneficial ownership of these securities and this report shall not be deemed an admission that NLBA I or NLV Management III are beneficial owners of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"(Continuation from footnote 6) Each of the Members may be deemed to have shared voting and dispositive power of these securities. Each of the Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":1991884,"source":{"system":"sec-edgar","filing":"0000899243-19-022047","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1625657/000089924319022047/doc4.xml","form_type":"4"}},{"id":3434002,"issuer":{"id":90033,"kind":"organization","name":"Deciphera Pharmaceuticals, Inc.","symbol":"NA"},"owners":[{"id":93222,"kind":"person","name":"New Leaf Venture Management III, L.L.C.","position":1,"cik":"0001625657","reported_name":"New Leaf Venture Management III, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93220,"kind":"person","name":"New Leaf Ventures III, L.P.","position":2,"cik":"0001625653","reported_name":"New Leaf Ventures III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":155397,"kind":"organization","name":"New Leaf Biopharma Opportunities I, L.P.","position":3,"cik":"0001625696","reported_name":"New Leaf Biopharma Opportunities I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93221,"kind":"person","name":"New Leaf Venture Associates III, L.P.","position":4,"cik":"0001625656","reported_name":"New Leaf Venture Associates III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":155398,"kind":"organization","name":"New Leaf BPO Associates I, L.P.","position":5,"cik":"0001625693","reported_name":"New Leaf BPO Associates I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-08-19T16:35:47.000Z","date":"2019-08-15","kind":"sale","acquired":false,"shares":78450,"price":36.0911,"value":2831346.795,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.00 to $36.64, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"The reportable securities are owned directly by New Leaf Biopharma Opportunities I, L.P. (\"Biopharma I\"). New Leaf BPO Associates I, L.P. (\"NLBA I\") is the sole general partner of Biopharma I. NLV Management III is the sole general partner of NLBA I. NLVP is the investment adviser of Biopharma I. Each of NLBA I and NLV Management III disclaim beneficial ownership of these securities and this report shall not be deemed an admission that NLBA I or NLV Management III are beneficial owners of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"(Continuation from footnote 6) Each of the Members may be deemed to have shared voting and dispositive power of these securities. Each of the Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":2067858,"source":{"system":"sec-edgar","filing":"0000899243-19-022047","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1625657/000089924319022047/doc4.xml","form_type":"4"}},{"id":3434001,"issuer":{"id":90033,"kind":"organization","name":"Deciphera Pharmaceuticals, Inc.","symbol":"NA"},"owners":[{"id":93222,"kind":"person","name":"New Leaf Venture Management III, L.L.C.","position":1,"cik":"0001625657","reported_name":"New Leaf Venture Management III, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93220,"kind":"person","name":"New Leaf Ventures III, L.P.","position":2,"cik":"0001625653","reported_name":"New Leaf Ventures III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":155397,"kind":"organization","name":"New Leaf Biopharma Opportunities I, L.P.","position":3,"cik":"0001625696","reported_name":"New Leaf Biopharma Opportunities I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93221,"kind":"person","name":"New Leaf Venture Associates III, L.P.","position":4,"cik":"0001625656","reported_name":"New Leaf Venture Associates III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":155398,"kind":"organization","name":"New Leaf BPO Associates I, L.P.","position":5,"cik":"0001625693","reported_name":"New Leaf BPO Associates I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-08-19T16:35:47.000Z","date":"2019-08-16","kind":"sale","acquired":false,"shares":26108,"price":37.0148,"value":966382.3984,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.00 to $37.32, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (5) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reportable securities are owned directly by New Leaf Ventures III, L.P. (\"NLV III\"). New Leaf Venture Associates III, L.P. (\"NLV Associates III\") is the sole general partner of NLV III. New Leaf Venture Management III, L.L.C. (\"NLV Management III\") is the sole general partner of NLV Associates III. New Leaf Venture Partners, L.L.C. (\"NLVP\") is the investment adviser of NLV III. Each of NLV Associates III and NLV Management III disclaim beneficial ownership of these securities and this report shall not be deemed an admission that NLV Associates III or NLV Management III are beneficial owners of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"(Continuation from footnote 2) Each of Ronald M. Hunt and Vijay K. Lathi (each, a \"Member\" and collectively, the \"Members\") is a member of NLV Management III and may be deemed to have shared voting and dispositive power of these securities. Each of the Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":1790882,"source":{"system":"sec-edgar","filing":"0000899243-19-022047","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1625657/000089924319022047/doc4.xml","form_type":"4"}},{"id":3434000,"issuer":{"id":90033,"kind":"organization","name":"Deciphera Pharmaceuticals, Inc.","symbol":"NA"},"owners":[{"id":93222,"kind":"person","name":"New Leaf Venture Management III, L.L.C.","position":1,"cik":"0001625657","reported_name":"New Leaf Venture Management III, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93220,"kind":"person","name":"New Leaf Ventures III, L.P.","position":2,"cik":"0001625653","reported_name":"New Leaf Ventures III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":155397,"kind":"organization","name":"New Leaf Biopharma Opportunities I, L.P.","position":3,"cik":"0001625696","reported_name":"New Leaf Biopharma Opportunities I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93221,"kind":"person","name":"New Leaf Venture Associates III, L.P.","position":4,"cik":"0001625656","reported_name":"New Leaf Venture Associates III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":155398,"kind":"organization","name":"New Leaf BPO Associates I, L.P.","position":5,"cik":"0001625693","reported_name":"New Leaf BPO Associates I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-08-19T16:35:47.000Z","date":"2019-08-16","kind":"sale","acquired":false,"shares":69292,"price":36.5433,"value":2532158.3436,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.00 to $36.995, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reportable securities are owned directly by New Leaf Ventures III, L.P. (\"NLV III\"). New Leaf Venture Associates III, L.P. (\"NLV Associates III\") is the sole general partner of NLV III. New Leaf Venture Management III, L.L.C. (\"NLV Management III\") is the sole general partner of NLV Associates III. New Leaf Venture Partners, L.L.C. (\"NLVP\") is the investment adviser of NLV III. Each of NLV Associates III and NLV Management III disclaim beneficial ownership of these securities and this report shall not be deemed an admission that NLV Associates III or NLV Management III are beneficial owners of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"(Continuation from footnote 2) Each of Ronald M. Hunt and Vijay K. Lathi (each, a \"Member\" and collectively, the \"Members\") is a member of NLV Management III and may be deemed to have shared voting and dispositive power of these securities. Each of the Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":1816990,"source":{"system":"sec-edgar","filing":"0000899243-19-022047","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1625657/000089924319022047/doc4.xml","form_type":"4"}},{"id":3433999,"issuer":{"id":90033,"kind":"organization","name":"Deciphera Pharmaceuticals, Inc.","symbol":"NA"},"owners":[{"id":93222,"kind":"person","name":"New Leaf Venture Management III, L.L.C.","position":1,"cik":"0001625657","reported_name":"New Leaf Venture Management III, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93220,"kind":"person","name":"New Leaf Ventures III, L.P.","position":2,"cik":"0001625653","reported_name":"New Leaf Ventures III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":155397,"kind":"organization","name":"New Leaf Biopharma Opportunities I, L.P.","position":3,"cik":"0001625696","reported_name":"New Leaf Biopharma Opportunities I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93221,"kind":"person","name":"New Leaf Venture Associates III, L.P.","position":4,"cik":"0001625656","reported_name":"New Leaf Venture Associates III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":155398,"kind":"organization","name":"New Leaf BPO Associates I, L.P.","position":5,"cik":"0001625693","reported_name":"New Leaf BPO Associates I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-08-19T16:35:47.000Z","date":"2019-08-15","kind":"sale","acquired":false,"shares":71550,"price":36.0911,"value":2582318.205,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.00 to $36.64, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reportable securities are owned directly by New Leaf Ventures III, L.P. (\"NLV III\"). New Leaf Venture Associates III, L.P. (\"NLV Associates III\") is the sole general partner of NLV III. New Leaf Venture Management III, L.L.C. (\"NLV Management III\") is the sole general partner of NLV Associates III. New Leaf Venture Partners, L.L.C. (\"NLVP\") is the investment adviser of NLV III. Each of NLV Associates III and NLV Management III disclaim beneficial ownership of these securities and this report shall not be deemed an admission that NLV Associates III or NLV Management III are beneficial owners of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"(Continuation from footnote 2) Each of Ronald M. Hunt and Vijay K. Lathi (each, a \"Member\" and collectively, the \"Members\") is a member of NLV Management III and may be deemed to have shared voting and dispositive power of these securities. Each of the Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":1886282,"source":{"system":"sec-edgar","filing":"0000899243-19-022047","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1625657/000089924319022047/doc4.xml","form_type":"4"}},{"id":3883196,"issuer":{"id":120922,"kind":"organization","name":"Aptinyx Inc.","symbol":"APTX"},"owners":[{"id":93222,"kind":"person","name":"New Leaf Venture Management III, L.L.C.","position":1,"cik":"0001625657","reported_name":"New Leaf Venture Management III, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93221,"kind":"person","name":"New Leaf Venture Associates III, L.P.","position":2,"cik":"0001625656","reported_name":"New Leaf Venture Associates III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93220,"kind":"person","name":"New Leaf Ventures III, L.P.","position":3,"cik":"0001625653","reported_name":"New Leaf Ventures III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":155397,"kind":"organization","name":"New Leaf Biopharma Opportunities I, L.P.","position":4,"cik":"0001625696","reported_name":"New Leaf Biopharma Opportunities I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":155398,"kind":"organization","name":"New Leaf BPO Associates I, L.P.","position":5,"cik":"0001625693","reported_name":"New Leaf BPO Associates I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Convertible Preferred Stock","published_at":"2018-06-26T16:57:11.000Z","date":"2018-06-25","kind":"exercise","acquired":false,"shares":6712986,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of  Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or additional consideration.  The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of  Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or additional consideration.  The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of  Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or additional consideration.  The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of  Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or additional consideration.  The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These shares are held directly by New Leaf Ventures Biopharma Opportunities I, L.P. (\"NLV Biopharma\"). The general partner of NLV Biopharma is New Leaf BPO Associates I, L.P. (\"NLBA-I\"). The general partner of NLBA-I is Management-III. Each of NLBA-I and Management-III may be deemed to have sole voting and investment power with respect to these securities. Each of NLBA-I and Management-III disclaim beneficial ownership of these securities and this report shall not be deemed an admission that NLBA-I or Management-III are beneficial owners of such securities for purposes of Section 16 or any other purpose, except to the extent of their respective pecuniary interests therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Each of the Managers may be deemed to have shared voting and investment power with respect to these securities. Each of the Managers disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":243345},"source":{"system":"sec-edgar","filing":"0001104659-18-042317","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1674365/000110465918042317/a4.xml","form_type":"4"}},{"id":3883195,"issuer":{"id":120922,"kind":"organization","name":"Aptinyx Inc.","symbol":"APTX"},"owners":[{"id":93222,"kind":"person","name":"New Leaf Venture Management III, L.L.C.","position":1,"cik":"0001625657","reported_name":"New Leaf Venture Management III, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93221,"kind":"person","name":"New Leaf Venture Associates III, L.P.","position":2,"cik":"0001625656","reported_name":"New Leaf Venture Associates III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93220,"kind":"person","name":"New Leaf Ventures III, L.P.","position":3,"cik":"0001625653","reported_name":"New Leaf Ventures III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":155397,"kind":"organization","name":"New Leaf Biopharma Opportunities I, L.P.","position":4,"cik":"0001625696","reported_name":"New Leaf Biopharma Opportunities I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":155398,"kind":"organization","name":"New Leaf BPO Associates I, L.P.","position":5,"cik":"0001625693","reported_name":"New Leaf BPO Associates I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Convertible Preferred Stock","published_at":"2018-06-26T16:57:11.000Z","date":"2018-06-25","kind":"exercise","acquired":false,"shares":15233315,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of  Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or additional consideration.  The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of  Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or additional consideration.  The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of  Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or additional consideration.  The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of  Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or additional consideration.  The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held directly by New Leaf Ventures III, L.P. (\"NLV-III\"). The general partner of NLV-III is New Leaf Venture Associates III, L.P. (\"NLVA-III\"). The general partner of NLVA-III is New Leaf Venture Management III, L.L.C. (\"Management-III\"). Each of NLVA-III and Management-III may be deemed to have sole voting and investment power with respect to these securities. Each of NLVA-III and Management-III disclaim beneficial ownership of these securities and this report shall not be deemed an admission that NLVA-III or Management-III are beneficial owners of such securities for purposes of Section 16 or any other purpose, except to the extent of their respective pecuniary interests therein. Liam T. Ratcliffe, a member of the Issuer's board of directors, Ronald M. Hunt and Vijay K. Lathi are the managers of Management-III (each, a \"Manager\" and collectively, the \"Managers\") and may each be deemed to have shared voting and investment power with respect to these securities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of the Managers disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":552208},"source":{"system":"sec-edgar","filing":"0001104659-18-042317","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1674365/000110465918042317/a4.xml","form_type":"4"}},{"id":3883194,"issuer":{"id":120922,"kind":"organization","name":"Aptinyx Inc.","symbol":"APTX"},"owners":[{"id":93222,"kind":"person","name":"New Leaf Venture Management III, L.L.C.","position":1,"cik":"0001625657","reported_name":"New Leaf Venture Management III, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93221,"kind":"person","name":"New Leaf Venture Associates III, L.P.","position":2,"cik":"0001625656","reported_name":"New Leaf Venture Associates III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93220,"kind":"person","name":"New Leaf Ventures III, L.P.","position":3,"cik":"0001625653","reported_name":"New Leaf Ventures III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":155397,"kind":"organization","name":"New Leaf Biopharma Opportunities I, L.P.","position":4,"cik":"0001625696","reported_name":"New Leaf Biopharma Opportunities I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":155398,"kind":"organization","name":"New Leaf BPO Associates I, L.P.","position":5,"cik":"0001625693","reported_name":"New Leaf BPO Associates I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A-2 Convertible Preferred Stock","published_at":"2018-06-26T16:57:11.000Z","date":"2018-06-25","kind":"exercise","acquired":false,"shares":33022786,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of  Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or additional consideration.  The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of  Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or additional consideration.  The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of  Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or additional consideration.  The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of  Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or additional consideration.  The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held directly by New Leaf Ventures III, L.P. (\"NLV-III\"). The general partner of NLV-III is New Leaf Venture Associates III, L.P. (\"NLVA-III\"). The general partner of NLVA-III is New Leaf Venture Management III, L.L.C. (\"Management-III\"). Each of NLVA-III and Management-III may be deemed to have sole voting and investment power with respect to these securities. Each of NLVA-III and Management-III disclaim beneficial ownership of these securities and this report shall not be deemed an admission that NLVA-III or Management-III are beneficial owners of such securities for purposes of Section 16 or any other purpose, except to the extent of their respective pecuniary interests therein. Liam T. Ratcliffe, a member of the Issuer's board of directors, Ronald M. Hunt and Vijay K. Lathi are the managers of Management-III (each, a \"Manager\" and collectively, the \"Managers\") and may each be deemed to have shared voting and investment power with respect to these securities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of the Managers disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1197076},"source":{"system":"sec-edgar","filing":"0001104659-18-042317","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1674365/000110465918042317/a4.xml","form_type":"4"}},{"id":3883193,"issuer":{"id":120922,"kind":"organization","name":"Aptinyx Inc.","symbol":"APTX"},"owners":[{"id":93222,"kind":"person","name":"New Leaf Venture Management III, L.L.C.","position":1,"cik":"0001625657","reported_name":"New Leaf Venture Management III, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93221,"kind":"person","name":"New Leaf Venture Associates III, L.P.","position":2,"cik":"0001625656","reported_name":"New Leaf Venture Associates III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93220,"kind":"person","name":"New Leaf Ventures III, L.P.","position":3,"cik":"0001625653","reported_name":"New Leaf Ventures III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":155397,"kind":"organization","name":"New Leaf Biopharma Opportunities I, L.P.","position":4,"cik":"0001625696","reported_name":"New Leaf Biopharma Opportunities I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":155398,"kind":"organization","name":"New Leaf BPO Associates I, L.P.","position":5,"cik":"0001625693","reported_name":"New Leaf BPO Associates I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A-1 Convertible Preferred Stock","published_at":"2018-06-26T16:57:11.000Z","date":"2018-06-25","kind":"exercise","acquired":false,"shares":28895188,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of  Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or additional consideration.  The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of  Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or additional consideration.  The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of  Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or additional consideration.  The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of  Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or additional consideration.  The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held directly by New Leaf Ventures III, L.P. (\"NLV-III\"). The general partner of NLV-III is New Leaf Venture Associates III, L.P. (\"NLVA-III\"). The general partner of NLVA-III is New Leaf Venture Management III, L.L.C. (\"Management-III\"). Each of NLVA-III and Management-III may be deemed to have sole voting and investment power with respect to these securities. Each of NLVA-III and Management-III disclaim beneficial ownership of these securities and this report shall not be deemed an admission that NLVA-III or Management-III are beneficial owners of such securities for purposes of Section 16 or any other purpose, except to the extent of their respective pecuniary interests therein. Liam T. Ratcliffe, a member of the Issuer's board of directors, Ronald M. Hunt and Vijay K. Lathi are the managers of Management-III (each, a \"Manager\" and collectively, the \"Managers\") and may each be deemed to have shared voting and investment power with respect to these securities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of the Managers disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1047450},"source":{"system":"sec-edgar","filing":"0001104659-18-042317","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1674365/000110465918042317/a4.xml","form_type":"4"}},{"id":3883192,"issuer":{"id":120922,"kind":"organization","name":"Aptinyx Inc.","symbol":"APTX"},"owners":[{"id":93222,"kind":"person","name":"New Leaf Venture Management III, L.L.C.","position":1,"cik":"0001625657","reported_name":"New Leaf Venture Management III, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93221,"kind":"person","name":"New Leaf Venture Associates III, L.P.","position":2,"cik":"0001625656","reported_name":"New Leaf Venture Associates III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93220,"kind":"person","name":"New Leaf Ventures III, L.P.","position":3,"cik":"0001625653","reported_name":"New Leaf Ventures III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":155397,"kind":"organization","name":"New Leaf Biopharma Opportunities I, L.P.","position":4,"cik":"0001625696","reported_name":"New Leaf Biopharma Opportunities I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":155398,"kind":"organization","name":"New Leaf BPO Associates I, L.P.","position":5,"cik":"0001625693","reported_name":"New Leaf BPO Associates I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-06-26T16:57:11.000Z","date":"2018-06-25","kind":"purchase","acquired":true,"shares":125000,"price":16,"value":2000000.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F6","text":"On June 25, 2018, each of NLV-III and NLV Biopharma purchased 125,000 and 125,000 shares of common stock of the Issuer at a price of $16.00 per share, respectively, pursuant to an underwritten public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These shares are held directly by New Leaf Ventures Biopharma Opportunities I, L.P. (\"NLV Biopharma\"). The general partner of NLV Biopharma is New Leaf BPO Associates I, L.P. (\"NLBA-I\"). The general partner of NLBA-I is Management-III. Each of NLBA-I and Management-III may be deemed to have sole voting and investment power with respect to these securities. Each of NLBA-I and Management-III disclaim beneficial ownership of these securities and this report shall not be deemed an admission that NLBA-I or Management-III are beneficial owners of such securities for purposes of Section 16 or any other purpose, except to the extent of their respective pecuniary interests therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Each of the Managers may be deemed to have shared voting and investment power with respect to these securities. Each of the Managers disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":368345,"source":{"system":"sec-edgar","filing":"0001104659-18-042317","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1674365/000110465918042317/a4.xml","form_type":"4"}},{"id":3883191,"issuer":{"id":120922,"kind":"organization","name":"Aptinyx Inc.","symbol":"APTX"},"owners":[{"id":93222,"kind":"person","name":"New Leaf Venture Management III, L.L.C.","position":1,"cik":"0001625657","reported_name":"New Leaf Venture Management III, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93221,"kind":"person","name":"New Leaf Venture Associates III, L.P.","position":2,"cik":"0001625656","reported_name":"New Leaf Venture Associates III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93220,"kind":"person","name":"New Leaf Ventures III, L.P.","position":3,"cik":"0001625653","reported_name":"New Leaf Ventures III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":155397,"kind":"organization","name":"New Leaf Biopharma Opportunities I, L.P.","position":4,"cik":"0001625696","reported_name":"New Leaf Biopharma Opportunities I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":155398,"kind":"organization","name":"New Leaf BPO Associates I, L.P.","position":5,"cik":"0001625693","reported_name":"New Leaf BPO Associates I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-06-26T16:57:11.000Z","date":"2018-06-25","kind":"purchase","acquired":true,"shares":125000,"price":16,"value":2000000.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F6","text":"On June 25, 2018, each of NLV-III and NLV Biopharma purchased 125,000 and 125,000 shares of common stock of the Issuer at a price of $16.00 per share, respectively, pursuant to an underwritten public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held directly by New Leaf Ventures III, L.P. (\"NLV-III\"). The general partner of NLV-III is New Leaf Venture Associates III, L.P. (\"NLVA-III\"). The general partner of NLVA-III is New Leaf Venture Management III, L.L.C. (\"Management-III\"). Each of NLVA-III and Management-III may be deemed to have sole voting and investment power with respect to these securities. Each of NLVA-III and Management-III disclaim beneficial ownership of these securities and this report shall not be deemed an admission that NLVA-III or Management-III are beneficial owners of such securities for purposes of Section 16 or any other purpose, except to the extent of their respective pecuniary interests therein. Liam T. Ratcliffe, a member of the Issuer's board of directors, Ronald M. Hunt and Vijay K. Lathi are the managers of Management-III (each, a \"Manager\" and collectively, the \"Managers\") and may each be deemed to have shared voting and investment power with respect to these securities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of the Managers disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":2921734,"source":{"system":"sec-edgar","filing":"0001104659-18-042317","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1674365/000110465918042317/a4.xml","form_type":"4"}},{"id":3883190,"issuer":{"id":120922,"kind":"organization","name":"Aptinyx Inc.","symbol":"APTX"},"owners":[{"id":93222,"kind":"person","name":"New Leaf Venture Management III, L.L.C.","position":1,"cik":"0001625657","reported_name":"New Leaf Venture Management III, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93221,"kind":"person","name":"New Leaf Venture Associates III, L.P.","position":2,"cik":"0001625656","reported_name":"New Leaf Venture Associates III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93220,"kind":"person","name":"New Leaf Ventures III, L.P.","position":3,"cik":"0001625653","reported_name":"New Leaf Ventures III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":155397,"kind":"organization","name":"New Leaf Biopharma Opportunities I, L.P.","position":4,"cik":"0001625696","reported_name":"New Leaf Biopharma Opportunities I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":155398,"kind":"organization","name":"New Leaf BPO Associates I, L.P.","position":5,"cik":"0001625693","reported_name":"New Leaf BPO Associates I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-06-26T16:57:11.000Z","date":"2018-06-25","kind":"exercise","acquired":true,"shares":243345,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Each share of  Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or additional consideration.  The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of  Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or additional consideration.  The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These shares are held directly by New Leaf Ventures Biopharma Opportunities I, L.P. (\"NLV Biopharma\"). The general partner of NLV Biopharma is New Leaf BPO Associates I, L.P. (\"NLBA-I\"). The general partner of NLBA-I is Management-III. Each of NLBA-I and Management-III may be deemed to have sole voting and investment power with respect to these securities. Each of NLBA-I and Management-III disclaim beneficial ownership of these securities and this report shall not be deemed an admission that NLBA-I or Management-III are beneficial owners of such securities for purposes of Section 16 or any other purpose, except to the extent of their respective pecuniary interests therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Each of the Managers may be deemed to have shared voting and investment power with respect to these securities. Each of the Managers disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":243345,"source":{"system":"sec-edgar","filing":"0001104659-18-042317","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1674365/000110465918042317/a4.xml","form_type":"4"}},{"id":3883189,"issuer":{"id":120922,"kind":"organization","name":"Aptinyx Inc.","symbol":"APTX"},"owners":[{"id":93222,"kind":"person","name":"New Leaf Venture Management III, L.L.C.","position":1,"cik":"0001625657","reported_name":"New Leaf Venture Management III, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93221,"kind":"person","name":"New Leaf Venture Associates III, L.P.","position":2,"cik":"0001625656","reported_name":"New Leaf Venture Associates III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93220,"kind":"person","name":"New Leaf Ventures III, L.P.","position":3,"cik":"0001625653","reported_name":"New Leaf Ventures III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":155397,"kind":"organization","name":"New Leaf Biopharma Opportunities I, L.P.","position":4,"cik":"0001625696","reported_name":"New Leaf Biopharma Opportunities I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":155398,"kind":"organization","name":"New Leaf BPO Associates I, L.P.","position":5,"cik":"0001625693","reported_name":"New Leaf BPO Associates I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-06-26T16:57:11.000Z","date":"2018-06-25","kind":"exercise","acquired":true,"shares":552208,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Each share of  Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or additional consideration.  The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of  Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or additional consideration.  The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held directly by New Leaf Ventures III, L.P. (\"NLV-III\"). The general partner of NLV-III is New Leaf Venture Associates III, L.P. (\"NLVA-III\"). The general partner of NLVA-III is New Leaf Venture Management III, L.L.C. (\"Management-III\"). Each of NLVA-III and Management-III may be deemed to have sole voting and investment power with respect to these securities. Each of NLVA-III and Management-III disclaim beneficial ownership of these securities and this report shall not be deemed an admission that NLVA-III or Management-III are beneficial owners of such securities for purposes of Section 16 or any other purpose, except to the extent of their respective pecuniary interests therein. Liam T. Ratcliffe, a member of the Issuer's board of directors, Ronald M. Hunt and Vijay K. Lathi are the managers of Management-III (each, a \"Manager\" and collectively, the \"Managers\") and may each be deemed to have shared voting and investment power with respect to these securities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of the Managers disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":2796734,"source":{"system":"sec-edgar","filing":"0001104659-18-042317","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1674365/000110465918042317/a4.xml","form_type":"4"}},{"id":3883188,"issuer":{"id":120922,"kind":"organization","name":"Aptinyx Inc.","symbol":"APTX"},"owners":[{"id":93222,"kind":"person","name":"New Leaf Venture Management III, L.L.C.","position":1,"cik":"0001625657","reported_name":"New Leaf Venture Management III, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93221,"kind":"person","name":"New Leaf Venture Associates III, L.P.","position":2,"cik":"0001625656","reported_name":"New Leaf Venture Associates III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93220,"kind":"person","name":"New Leaf Ventures III, L.P.","position":3,"cik":"0001625653","reported_name":"New Leaf Ventures III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":155397,"kind":"organization","name":"New Leaf Biopharma Opportunities I, L.P.","position":4,"cik":"0001625696","reported_name":"New Leaf Biopharma Opportunities I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":155398,"kind":"organization","name":"New Leaf BPO Associates I, L.P.","position":5,"cik":"0001625693","reported_name":"New Leaf BPO Associates I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-06-26T16:57:11.000Z","date":"2018-06-25","kind":"exercise","acquired":true,"shares":1197076,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Each share of  Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or additional consideration.  The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of  Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or additional consideration.  The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held directly by New Leaf Ventures III, L.P. (\"NLV-III\"). The general partner of NLV-III is New Leaf Venture Associates III, L.P. (\"NLVA-III\"). The general partner of NLVA-III is New Leaf Venture Management III, L.L.C. (\"Management-III\"). Each of NLVA-III and Management-III may be deemed to have sole voting and investment power with respect to these securities. Each of NLVA-III and Management-III disclaim beneficial ownership of these securities and this report shall not be deemed an admission that NLVA-III or Management-III are beneficial owners of such securities for purposes of Section 16 or any other purpose, except to the extent of their respective pecuniary interests therein. Liam T. Ratcliffe, a member of the Issuer's board of directors, Ronald M. Hunt and Vijay K. Lathi are the managers of Management-III (each, a \"Manager\" and collectively, the \"Managers\") and may each be deemed to have shared voting and investment power with respect to these securities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of the Managers disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":2244526,"source":{"system":"sec-edgar","filing":"0001104659-18-042317","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1674365/000110465918042317/a4.xml","form_type":"4"}},{"id":3883187,"issuer":{"id":120922,"kind":"organization","name":"Aptinyx Inc.","symbol":"APTX"},"owners":[{"id":93222,"kind":"person","name":"New Leaf Venture Management III, L.L.C.","position":1,"cik":"0001625657","reported_name":"New Leaf Venture Management III, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93221,"kind":"person","name":"New Leaf Venture Associates III, L.P.","position":2,"cik":"0001625656","reported_name":"New Leaf Venture Associates III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93220,"kind":"person","name":"New Leaf Ventures III, L.P.","position":3,"cik":"0001625653","reported_name":"New Leaf Ventures III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":155397,"kind":"organization","name":"New Leaf Biopharma Opportunities I, L.P.","position":4,"cik":"0001625696","reported_name":"New Leaf Biopharma Opportunities I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":155398,"kind":"organization","name":"New Leaf BPO Associates I, L.P.","position":5,"cik":"0001625693","reported_name":"New Leaf BPO Associates I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-06-26T16:57:11.000Z","date":"2018-06-25","kind":"exercise","acquired":true,"shares":1047450,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Each share of  Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or additional consideration.  The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of  Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or additional consideration.  The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held directly by New Leaf Ventures III, L.P. (\"NLV-III\"). The general partner of NLV-III is New Leaf Venture Associates III, L.P. (\"NLVA-III\"). The general partner of NLVA-III is New Leaf Venture Management III, L.L.C. (\"Management-III\"). Each of NLVA-III and Management-III may be deemed to have sole voting and investment power with respect to these securities. Each of NLVA-III and Management-III disclaim beneficial ownership of these securities and this report shall not be deemed an admission that NLVA-III or Management-III are beneficial owners of such securities for purposes of Section 16 or any other purpose, except to the extent of their respective pecuniary interests therein. Liam T. Ratcliffe, a member of the Issuer's board of directors, Ronald M. Hunt and Vijay K. Lathi are the managers of Management-III (each, a \"Manager\" and collectively, the \"Managers\") and may each be deemed to have shared voting and investment power with respect to these securities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of the Managers disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":1047450,"source":{"system":"sec-edgar","filing":"0001104659-18-042317","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1674365/000110465918042317/a4.xml","form_type":"4"}},{"id":4197318,"issuer":{"id":90033,"kind":"organization","name":"Deciphera Pharmaceuticals, Inc.","symbol":"NA"},"owners":[{"id":93222,"kind":"person","name":"New Leaf Venture Management III, L.L.C.","position":1,"cik":"0001625657","reported_name":"New Leaf Venture Management III, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93220,"kind":"person","name":"New Leaf Ventures III, L.P.","position":2,"cik":"0001625653","reported_name":"New Leaf Ventures III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":155397,"kind":"organization","name":"New Leaf Biopharma Opportunities I, L.P.","position":3,"cik":"0001625696","reported_name":"New Leaf Biopharma Opportunities I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93221,"kind":"person","name":"New Leaf Venture Associates III, L.P.","position":4,"cik":"0001625656","reported_name":"New Leaf Venture Associates III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":155398,"kind":"organization","name":"New Leaf BPO Associates I, L.P.","position":5,"cik":"0001625693","reported_name":"New Leaf BPO Associates I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Preferred Stock","published_at":"2017-10-02T16:42:16.000Z","date":"2017-10-02","kind":"exercise","acquired":false,"shares":65997,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into 5.65 shares of common stock of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into 5.65 shares of common stock of the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into 5.65 shares of common stock of the Issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The reportable securities are owned directly by New Leaf Biopharma Opportunities I, L.P. (\"Biopharma I\"). New Leaf BPO Associates I, L.P. (\"NLBA I\") is the sole general partner of Biopharma I. NLV Management III is the sole general partner of NLBA I. NLVP is the investment adviser of Biopharma I. Each of NLBA I and NLV Management III disclaim beneficial ownership of these securities and this report shall not be deemed an admission that NLBA I or NLV Management III are beneficial owners of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"(Continuation from footnote 4) Each of the Members may be deemed to have shared voting and dispositive power of these securities. Each of the Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":372883},"source":{"system":"sec-edgar","filing":"0000899243-17-023140","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1625657/000089924317023140/doc4.xml","form_type":"4"}},{"id":4197317,"issuer":{"id":90033,"kind":"organization","name":"Deciphera Pharmaceuticals, Inc.","symbol":"NA"},"owners":[{"id":93222,"kind":"person","name":"New Leaf Venture Management III, L.L.C.","position":1,"cik":"0001625657","reported_name":"New Leaf Venture Management III, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93220,"kind":"person","name":"New Leaf Ventures III, L.P.","position":2,"cik":"0001625653","reported_name":"New Leaf Ventures III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":155397,"kind":"organization","name":"New Leaf Biopharma Opportunities I, L.P.","position":3,"cik":"0001625696","reported_name":"New Leaf Biopharma Opportunities I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93221,"kind":"person","name":"New Leaf Venture Associates III, L.P.","position":4,"cik":"0001625656","reported_name":"New Leaf Venture Associates III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":155398,"kind":"organization","name":"New Leaf BPO Associates I, L.P.","position":5,"cik":"0001625693","reported_name":"New Leaf BPO Associates I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B-2 Preferred Stock","published_at":"2017-10-02T16:42:16.000Z","date":"2017-10-02","kind":"exercise","acquired":false,"shares":198004,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into 5.65 shares of common stock of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into 5.65 shares of common stock of the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into 5.65 shares of common stock of the Issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The reportable securities are owned directly by New Leaf Biopharma Opportunities I, L.P. (\"Biopharma I\"). New Leaf BPO Associates I, L.P. (\"NLBA I\") is the sole general partner of Biopharma I. NLV Management III is the sole general partner of NLBA I. NLVP is the investment adviser of Biopharma I. Each of NLBA I and NLV Management III disclaim beneficial ownership of these securities and this report shall not be deemed an admission that NLBA I or NLV Management III are beneficial owners of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"(Continuation from footnote 4) Each of the Members may be deemed to have shared voting and dispositive power of these securities. Each of the Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1118722},"source":{"system":"sec-edgar","filing":"0000899243-17-023140","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1625657/000089924317023140/doc4.xml","form_type":"4"}},{"id":4197316,"issuer":{"id":90033,"kind":"organization","name":"Deciphera Pharmaceuticals, Inc.","symbol":"NA"},"owners":[{"id":93222,"kind":"person","name":"New Leaf Venture Management III, L.L.C.","position":1,"cik":"0001625657","reported_name":"New Leaf Venture Management III, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93220,"kind":"person","name":"New Leaf Ventures III, L.P.","position":2,"cik":"0001625653","reported_name":"New Leaf Ventures III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":155397,"kind":"organization","name":"New Leaf Biopharma Opportunities I, L.P.","position":3,"cik":"0001625696","reported_name":"New Leaf Biopharma Opportunities I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93221,"kind":"person","name":"New Leaf Venture Associates III, L.P.","position":4,"cik":"0001625656","reported_name":"New Leaf Venture Associates III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":155398,"kind":"organization","name":"New Leaf BPO Associates I, L.P.","position":5,"cik":"0001625693","reported_name":"New Leaf BPO Associates I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B-1 Preferred Stock","published_at":"2017-10-02T16:42:16.000Z","date":"2017-10-02","kind":"exercise","acquired":false,"shares":49505,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into 5.65 shares of common stock of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into 5.65 shares of common stock of the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into 5.65 shares of common stock of the Issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The reportable securities are owned directly by New Leaf Biopharma Opportunities I, L.P. (\"Biopharma I\"). New Leaf BPO Associates I, L.P. (\"NLBA I\") is the sole general partner of Biopharma I. NLV Management III is the sole general partner of NLBA I. NLVP is the investment adviser of Biopharma I. Each of NLBA I and NLV Management III disclaim beneficial ownership of these securities and this report shall not be deemed an admission that NLBA I or NLV Management III are beneficial owners of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"(Continuation from footnote 4) Each of the Members may be deemed to have shared voting and dispositive power of these securities. Each of the Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":279703},"source":{"system":"sec-edgar","filing":"0000899243-17-023140","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1625657/000089924317023140/doc4.xml","form_type":"4"}},{"id":4197315,"issuer":{"id":90033,"kind":"organization","name":"Deciphera Pharmaceuticals, Inc.","symbol":"NA"},"owners":[{"id":93222,"kind":"person","name":"New Leaf Venture Management III, L.L.C.","position":1,"cik":"0001625657","reported_name":"New Leaf Venture Management III, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93220,"kind":"person","name":"New Leaf Ventures III, L.P.","position":2,"cik":"0001625653","reported_name":"New Leaf Ventures III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":155397,"kind":"organization","name":"New Leaf Biopharma Opportunities I, L.P.","position":3,"cik":"0001625696","reported_name":"New Leaf Biopharma Opportunities I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93221,"kind":"person","name":"New Leaf Venture Associates III, L.P.","position":4,"cik":"0001625656","reported_name":"New Leaf Venture Associates III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":155398,"kind":"organization","name":"New Leaf BPO Associates I, L.P.","position":5,"cik":"0001625693","reported_name":"New Leaf BPO Associates I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B-2 Preferred Stock","published_at":"2017-10-02T16:42:16.000Z","date":"2017-10-02","kind":"exercise","acquired":false,"shares":198004,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into 5.65 shares of common stock of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into 5.65 shares of common stock of the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into 5.65 shares of common stock of the Issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reportable securities are owned directly by New Leaf Ventures III, L.P. (\"NLV III\"). New Leaf Venture Associates III, L.P. (\"NLV Associates III\") is the sole general partner of NLV III. New Leaf Venture Management III, L.L.C. (\"NLV Management III\") is the sole general partner of NLV Associates III. New Leaf Venture Partners, L.L.C. (\"NLVP\") is the investment adviser of NLV III. Each of NLV Associates III and NLV Management III disclaim beneficial ownership of these securities and this report shall not be deemed an admission that NLV Associates III or NLV Management III are beneficial owners of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"(Continuation from footnote 2) Each of Liam Ratcliffe, a member of the Issuer's board of directors, Jeani Delagardelle, Ronald M. Hunt and Vijay K. Lathi (each, a \"Member\" and collectively, the \"Members\") is a member of NLV Management III and may be deemed to have shared voting and dispositive power of these securities. Each of the Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1118722},"source":{"system":"sec-edgar","filing":"0000899243-17-023140","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1625657/000089924317023140/doc4.xml","form_type":"4"}},{"id":4197314,"issuer":{"id":90033,"kind":"organization","name":"Deciphera Pharmaceuticals, Inc.","symbol":"NA"},"owners":[{"id":93222,"kind":"person","name":"New Leaf Venture Management III, L.L.C.","position":1,"cik":"0001625657","reported_name":"New Leaf Venture Management III, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93220,"kind":"person","name":"New Leaf Ventures III, L.P.","position":2,"cik":"0001625653","reported_name":"New Leaf Ventures III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":155397,"kind":"organization","name":"New Leaf Biopharma Opportunities I, L.P.","position":3,"cik":"0001625696","reported_name":"New Leaf Biopharma Opportunities I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93221,"kind":"person","name":"New Leaf Venture Associates III, L.P.","position":4,"cik":"0001625656","reported_name":"New Leaf Venture Associates III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":155398,"kind":"organization","name":"New Leaf BPO Associates I, L.P.","position":5,"cik":"0001625693","reported_name":"New Leaf BPO Associates I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B-1 Preferred Stock","published_at":"2017-10-02T16:42:16.000Z","date":"2017-10-02","kind":"exercise","acquired":false,"shares":148515,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into 5.65 shares of common stock of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into 5.65 shares of common stock of the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into 5.65 shares of common stock of the Issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reportable securities are owned directly by New Leaf Ventures III, L.P. (\"NLV III\"). New Leaf Venture Associates III, L.P. (\"NLV Associates III\") is the sole general partner of NLV III. New Leaf Venture Management III, L.L.C. (\"NLV Management III\") is the sole general partner of NLV Associates III. New Leaf Venture Partners, L.L.C. (\"NLVP\") is the investment adviser of NLV III. Each of NLV Associates III and NLV Management III disclaim beneficial ownership of these securities and this report shall not be deemed an admission that NLV Associates III or NLV Management III are beneficial owners of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"(Continuation from footnote 2) Each of Liam Ratcliffe, a member of the Issuer's board of directors, Jeani Delagardelle, Ronald M. Hunt and Vijay K. Lathi (each, a \"Member\" and collectively, the \"Members\") is a member of NLV Management III and may be deemed to have shared voting and dispositive power of these securities. Each of the Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":839110},"source":{"system":"sec-edgar","filing":"0000899243-17-023140","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1625657/000089924317023140/doc4.xml","form_type":"4"}},{"id":4197313,"issuer":{"id":90033,"kind":"organization","name":"Deciphera Pharmaceuticals, Inc.","symbol":"NA"},"owners":[{"id":93222,"kind":"person","name":"New Leaf Venture Management III, L.L.C.","position":1,"cik":"0001625657","reported_name":"New Leaf Venture Management III, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93220,"kind":"person","name":"New Leaf Ventures III, L.P.","position":2,"cik":"0001625653","reported_name":"New Leaf Ventures III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":155397,"kind":"organization","name":"New Leaf Biopharma Opportunities I, L.P.","position":3,"cik":"0001625696","reported_name":"New Leaf Biopharma Opportunities I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93221,"kind":"person","name":"New Leaf Venture Associates III, L.P.","position":4,"cik":"0001625656","reported_name":"New Leaf Venture Associates III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":155398,"kind":"organization","name":"New Leaf BPO Associates I, L.P.","position":5,"cik":"0001625693","reported_name":"New Leaf BPO Associates I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-10-02T16:42:16.000Z","date":"2017-10-02","kind":"purchase","acquired":true,"shares":375000,"price":17,"value":6375000.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The reportable securities are owned directly by New Leaf Biopharma Opportunities I, L.P. (\"Biopharma I\"). New Leaf BPO Associates I, L.P. (\"NLBA I\") is the sole general partner of Biopharma I. NLV Management III is the sole general partner of NLBA I. NLVP is the investment adviser of Biopharma I. Each of NLBA I and NLV Management III disclaim beneficial ownership of these securities and this report shall not be deemed an admission that NLBA I or NLV Management III are beneficial owners of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"(Continuation from footnote 4) Each of the Members may be deemed to have shared voting and dispositive power of these securities. Each of the Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":2146308,"source":{"system":"sec-edgar","filing":"0000899243-17-023140","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1625657/000089924317023140/doc4.xml","form_type":"4"}},{"id":4197312,"issuer":{"id":90033,"kind":"organization","name":"Deciphera Pharmaceuticals, Inc.","symbol":"NA"},"owners":[{"id":93222,"kind":"person","name":"New Leaf Venture Management III, L.L.C.","position":1,"cik":"0001625657","reported_name":"New Leaf Venture Management III, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93220,"kind":"person","name":"New Leaf Ventures III, L.P.","position":2,"cik":"0001625653","reported_name":"New Leaf Ventures III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":155397,"kind":"organization","name":"New Leaf Biopharma Opportunities I, L.P.","position":3,"cik":"0001625696","reported_name":"New Leaf Biopharma Opportunities I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93221,"kind":"person","name":"New Leaf Venture Associates III, L.P.","position":4,"cik":"0001625656","reported_name":"New Leaf Venture Associates III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":155398,"kind":"organization","name":"New Leaf BPO Associates I, L.P.","position":5,"cik":"0001625693","reported_name":"New Leaf BPO Associates I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-10-02T16:42:16.000Z","date":"2017-10-02","kind":"exercise","acquired":true,"shares":372883,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into 5.65 shares of common stock of the Issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The reportable securities are owned directly by New Leaf Biopharma Opportunities I, L.P. (\"Biopharma I\"). New Leaf BPO Associates I, L.P. (\"NLBA I\") is the sole general partner of Biopharma I. NLV Management III is the sole general partner of NLBA I. NLVP is the investment adviser of Biopharma I. Each of NLBA I and NLV Management III disclaim beneficial ownership of these securities and this report shall not be deemed an admission that NLBA I or NLV Management III are beneficial owners of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"(Continuation from footnote 4) Each of the Members may be deemed to have shared voting and dispositive power of these securities. Each of the Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":1771308,"source":{"system":"sec-edgar","filing":"0000899243-17-023140","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1625657/000089924317023140/doc4.xml","form_type":"4"}},{"id":4197311,"issuer":{"id":90033,"kind":"organization","name":"Deciphera Pharmaceuticals, Inc.","symbol":"NA"},"owners":[{"id":93222,"kind":"person","name":"New Leaf Venture Management III, L.L.C.","position":1,"cik":"0001625657","reported_name":"New Leaf Venture Management III, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93220,"kind":"person","name":"New Leaf Ventures III, L.P.","position":2,"cik":"0001625653","reported_name":"New Leaf Ventures III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":155397,"kind":"organization","name":"New Leaf Biopharma Opportunities I, L.P.","position":3,"cik":"0001625696","reported_name":"New Leaf Biopharma Opportunities I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93221,"kind":"person","name":"New Leaf Venture Associates III, L.P.","position":4,"cik":"0001625656","reported_name":"New Leaf Venture Associates III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":155398,"kind":"organization","name":"New Leaf BPO Associates I, L.P.","position":5,"cik":"0001625693","reported_name":"New Leaf BPO Associates I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-10-02T16:42:16.000Z","date":"2017-10-02","kind":"exercise","acquired":true,"shares":1118722,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into 5.65 shares of common stock of the Issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The reportable securities are owned directly by New Leaf Biopharma Opportunities I, L.P. (\"Biopharma I\"). New Leaf BPO Associates I, L.P. (\"NLBA I\") is the sole general partner of Biopharma I. NLV Management III is the sole general partner of NLBA I. NLVP is the investment adviser of Biopharma I. Each of NLBA I and NLV Management III disclaim beneficial ownership of these securities and this report shall not be deemed an admission that NLBA I or NLV Management III are beneficial owners of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"(Continuation from footnote 4) Each of the Members may be deemed to have shared voting and dispositive power of these securities. Each of the Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":1398425,"source":{"system":"sec-edgar","filing":"0000899243-17-023140","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1625657/000089924317023140/doc4.xml","form_type":"4"}},{"id":4197310,"issuer":{"id":90033,"kind":"organization","name":"Deciphera Pharmaceuticals, Inc.","symbol":"NA"},"owners":[{"id":93222,"kind":"person","name":"New Leaf Venture Management III, L.L.C.","position":1,"cik":"0001625657","reported_name":"New Leaf Venture Management III, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93220,"kind":"person","name":"New Leaf Ventures III, L.P.","position":2,"cik":"0001625653","reported_name":"New Leaf Ventures III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":155397,"kind":"organization","name":"New Leaf Biopharma Opportunities I, L.P.","position":3,"cik":"0001625696","reported_name":"New Leaf Biopharma Opportunities I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93221,"kind":"person","name":"New Leaf Venture Associates III, L.P.","position":4,"cik":"0001625656","reported_name":"New Leaf Venture Associates III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":155398,"kind":"organization","name":"New Leaf BPO Associates I, L.P.","position":5,"cik":"0001625693","reported_name":"New Leaf BPO Associates I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-10-02T16:42:16.000Z","date":"2017-10-02","kind":"exercise","acquired":true,"shares":279703,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into 5.65 shares of common stock of the Issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The reportable securities are owned directly by New Leaf Biopharma Opportunities I, L.P. (\"Biopharma I\"). New Leaf BPO Associates I, L.P. (\"NLBA I\") is the sole general partner of Biopharma I. NLV Management III is the sole general partner of NLBA I. NLVP is the investment adviser of Biopharma I. Each of NLBA I and NLV Management III disclaim beneficial ownership of these securities and this report shall not be deemed an admission that NLBA I or NLV Management III are beneficial owners of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"(Continuation from footnote 4) Each of the Members may be deemed to have shared voting and dispositive power of these securities. Each of the Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":279703,"source":{"system":"sec-edgar","filing":"0000899243-17-023140","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1625657/000089924317023140/doc4.xml","form_type":"4"}},{"id":4197309,"issuer":{"id":90033,"kind":"organization","name":"Deciphera Pharmaceuticals, Inc.","symbol":"NA"},"owners":[{"id":93222,"kind":"person","name":"New Leaf Venture Management III, L.L.C.","position":1,"cik":"0001625657","reported_name":"New Leaf Venture Management III, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93220,"kind":"person","name":"New Leaf Ventures III, L.P.","position":2,"cik":"0001625653","reported_name":"New Leaf Ventures III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":155397,"kind":"organization","name":"New Leaf Biopharma Opportunities I, L.P.","position":3,"cik":"0001625696","reported_name":"New Leaf Biopharma Opportunities I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93221,"kind":"person","name":"New Leaf Venture Associates III, L.P.","position":4,"cik":"0001625656","reported_name":"New Leaf Venture Associates III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":155398,"kind":"organization","name":"New Leaf BPO Associates I, L.P.","position":5,"cik":"0001625693","reported_name":"New Leaf BPO Associates I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-10-02T16:42:16.000Z","date":"2017-10-02","kind":"exercise","acquired":true,"shares":1118722,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into 5.65 shares of common stock of the Issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reportable securities are owned directly by New Leaf Ventures III, L.P. (\"NLV III\"). New Leaf Venture Associates III, L.P. (\"NLV Associates III\") is the sole general partner of NLV III. New Leaf Venture Management III, L.L.C. (\"NLV Management III\") is the sole general partner of NLV Associates III. New Leaf Venture Partners, L.L.C. (\"NLVP\") is the investment adviser of NLV III. Each of NLV Associates III and NLV Management III disclaim beneficial ownership of these securities and this report shall not be deemed an admission that NLV Associates III or NLV Management III are beneficial owners of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"(Continuation from footnote 2) Each of Liam Ratcliffe, a member of the Issuer's board of directors, Jeani Delagardelle, Ronald M. Hunt and Vijay K. Lathi (each, a \"Member\" and collectively, the \"Members\") is a member of NLV Management III and may be deemed to have shared voting and dispositive power of these securities. Each of the Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":1957832,"source":{"system":"sec-edgar","filing":"0000899243-17-023140","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1625657/000089924317023140/doc4.xml","form_type":"4"}},{"id":4197308,"issuer":{"id":90033,"kind":"organization","name":"Deciphera Pharmaceuticals, Inc.","symbol":"NA"},"owners":[{"id":93222,"kind":"person","name":"New Leaf Venture Management III, L.L.C.","position":1,"cik":"0001625657","reported_name":"New Leaf Venture Management III, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93220,"kind":"person","name":"New Leaf Ventures III, L.P.","position":2,"cik":"0001625653","reported_name":"New Leaf Ventures III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":155397,"kind":"organization","name":"New Leaf Biopharma Opportunities I, L.P.","position":3,"cik":"0001625696","reported_name":"New Leaf Biopharma Opportunities I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":93221,"kind":"person","name":"New Leaf Venture Associates III, L.P.","position":4,"cik":"0001625656","reported_name":"New Leaf Venture Associates III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":155398,"kind":"organization","name":"New Leaf BPO Associates I, L.P.","position":5,"cik":"0001625693","reported_name":"New Leaf BPO Associates I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-10-02T16:42:16.000Z","date":"2017-10-02","kind":"exercise","acquired":true,"shares":839110,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into 5.65 shares of common stock of the Issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reportable securities are owned directly by New Leaf Ventures III, L.P. (\"NLV III\"). New Leaf Venture Associates III, L.P. (\"NLV Associates III\") is the sole general partner of NLV III. New Leaf Venture Management III, L.L.C. (\"NLV Management III\") is the sole general partner of NLV Associates III. New Leaf Venture Partners, L.L.C. (\"NLVP\") is the investment adviser of NLV III. Each of NLV Associates III and NLV Management III disclaim beneficial ownership of these securities and this report shall not be deemed an admission that NLV Associates III or NLV Management III are beneficial owners of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"(Continuation from footnote 2) Each of Liam Ratcliffe, a member of the Issuer's board of directors, Jeani Delagardelle, Ronald M. Hunt and Vijay K. Lathi (each, a \"Member\" and collectively, the \"Members\") is a member of NLV Management III and may be deemed to have shared voting and dispositive power of these securities. Each of the Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":839110,"source":{"system":"sec-edgar","filing":"0000899243-17-023140","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1625657/000089924317023140/doc4.xml","form_type":"4"}}]}